ClinicalTrialsFinder
RecruitingPhase 1Phase 2NCT06834035

Targeting Collagen VII Antibodies With IV IgG in Dystrophic Epidermolysis Bullosa

Sponsor

M. Peter Marinkovich

Enrollment

8 participants

Start Date

Aug 4, 2025

Study Type

INTERVENTIONAL

Conditions

Recessive dystrophic epidermolysis bullosaEpidermolysis BullosaDystrophic Epidermolysis BullosaEpidermolysis Bullosa Acquisita

Summary

The study objective is to see if IV IgG treatment in Recessive Dystrophic Epidermolysis Bullosa (RDEB) skin in conjunction with VYJUVEK treatment improves wound healing and affects the levels of C7 and HSV-1 antibody levels in serum. Fewer wounds, more rapidly healing wounds, and decreased C7 and HSV-1 antibodies could improve quality of life.

Eligibility

Min Age: 6 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a biological treatment called Immunoglobulin G for people with dystrophic epidermolysis bullosa, epidermolysis bullosa, and other related conditions. The study is currently recruiting participants at 1 location.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

BIOLOGICALImmunoglobulin G

Purified IgG from human serum, delivered via IV

Locations(1)

Stanford University

Redwood City, California, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06834035

Related Trials

A Phase 2 Study of TCP-25 Gel in Patients With Epidermolysis Bullosa, STEP-study

NCT065943939 locations

A Long-Term Safety Follow-up Registry for Patients Who Received Treatment With Prademagene Zamikeracel for Recessive Dystrophic Epidermolysis Bullosa (RDEB) in the Post-Marketing Setting

NCT077009664 locations

GMEB-SASS: A Gene-Modified Skin Substitute for RDEB Treatment

NCT071931341 location

A Study Comparing KB803 and Matched Placebo in Patients With Dystrophic Epidermolysis Bullosa

NCT070167505 locations

A Study to Learn About the Safety and Efficacy of the Drug Oleogel-S10 in Japanese Patients With Epidermolysis Bullosa

NCT069176906 locations